Generic Name and Formulations:
Citalopram (as HBr) 10mg, 20mg+, 40mg+; tabs (+scored).
Indications for CELEXA:
Initially 20mg once daily; after ≥1 week may increase to 40mg once daily. Doses >40mg/day: not recommended. Elderly (>60yrs), hepatic impairment, CYP2C19 poor metabolizers, concomitant cimetidine or other CYP2C19 inhibitors: max 20mg/day. 3rd trimester pregnant women: consider tapering dose.
Concomitant pimozide, linezolid, IV methylene blue. During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of citalopram.
Increased risk of suicidal thinking and behavior in children, adolescents and young adults; monitor for clinical worsening and unusual changes. Congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent MI, uncompensated heart failure, or concomitant drugs that prolong the QT interval: not recommended; monitor ECG if therapy is considered. Correct hypokalemia, hypomagnesemia before starting and periodically monitor. Bipolar disorder. History of seizures or mania/hypomania. ECT. Monitor for serotonin syndrome; discontinue if occurs. Angle-closure glaucoma. Hepatic or severe renal impairment (CrCl <20mL/min). Volume-depleted. Avoid abrupt cessation. Reevaluate periodically. Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C) (avoid 3rd trimester; see full labeling for effects on neonate). Nursing mothers: not recommended.
See Contraindications. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Avoid drugs that prolong QT interval including Class 1A (eg, quinidine, procainamide) or Class III antiarrhythmics (eg, amiodarone, sotalol), antipsychotics (eg, chlorpromazine, thioridazine), antibiotics (eg, gatifloxacin, moxifloxacin), and others (eg, pentamidine, methadone, levomethadyl acetate). Avoid alcohol. Increased risk of bleeding with NSAIDs, aspirin, warfarin, and others that affect coagulation. May be potentiated by cimetidine, lithium, potent inhibitors of CYP2C19 or CYP3A4 (eg, azole antifungals). May be antagonized by carbamazepine. Increases metoprolol levels.
GI upset, dry mouth, somnolence, insomnia, increased sweating, anorexia, rhinitis, sexual dysfunction, agitation, fatigue, arthralgia, myalgia, hyponatremia (esp. elderly); dose-dependent QT prolongation.
Tabs—100; Soln—Contact supplier
Neurology Advisor Articles
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- A Convenient Truth: The Problem With Seizure Under-Reporting and How to Fix It
- Incidence of Serotonin Syndrome With Co-Prescription of Triptans, Antidepressants
- Idiopathic Parkinson Disease May Increase Risk for Overactive Bladder
- Palliative Care in Movement Disorders: Recommendations for Improvement
- Cannabinoids May Be Effective as Adjunctive Treatment for Refractory Epilepsy